Dana-Farber Cancer Institute, Boston, MA
Jason John Luke , Larry Rubinstein , Gary L Smith , S. Percy Ivy , Pamela Jo Harris
Response | All (937) |
Targeted (182) |
Chemo (186) |
Immuno (569) |
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total | % | 95% CI | Total | % | 95% CI | Total | % | 95% CI | Total | % | 95% CI | |
CR + PR | 59 | 6.3 | 4.8-8.1 | 4 | 2.2 | 0.6-5.5 | 14 | 7.5 | 4.2-12.3 | 41 | 7.2 | 5.2-9.7 |
SD | 192 | 20.5 | 59 | 32.4 | 53 | 28.5 | 80 | 14.0 | ||||
CB | 251 | 26.8 | 24.0-29.8 | 63 | 34.6 | 27.7-42.0 | 67 | 36.0 | 29.1-43.4 | 121 | 21.2 | 18.0-24.9 |
Not evaluated | 61 | 6.5 | 15 | 8.2 | 16 | 8.6 | 30 | 5.3 | ||||
PD | 625 | 66.7 | 104 | 57.1 | 103 | 55.4 | 418 | 73.3 | ||||
Toxicity | ||||||||||||
G3 | G4 | G3 | G4 | G3 | G4 | G3 | G4 | |||||
% | 42.2 | 12.1 | 42.3 | 9.3 | 46.2 | 23.7 | 40.8 | 9.1 | ||||
95% CI | 39.0-45.4 | 10.0-14.3 | 35.0-49.8 | 5.5-14.5 | 38.9-53.7 | 17.8-30.4 | 36.7-44.9 | 6.9-11.8 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Lingqiang Lai
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kohei Shitara
2023 ASCO Annual Meeting
First Author: Jesica Freeman
2023 ASCO Annual Meeting
First Author: Anika Kumar